Sutro Biopharma (STRO) Non-Current Deffered Revenue (2017 - 2025)

Sutro Biopharma has disclosed Non-Current Deffered Revenue across 9 years of filings, most recently posting $2.0 million for Q4 2025.

• Non-Current Deffered Revenue for Q4 2025 came in at $2.0 million, down 83.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 million (down 83.82% YoY), and the FY2025 annual result was $2.0 million, down 83.82% from the prior year.
• Non-Current Deffered Revenue came in at $2.0 million for Q4 2025 at Sutro Biopharma, down from $3.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $90.0 million in Q2 2022 to a low of $145000.0 in Q3 2021.
• The 5-year median for Non-Current Deffered Revenue is $19.8 million (2024), against an average of $37.5 million.
• Across the five-year window, Non-Current Deffered Revenue slumped 94.56% in 2021 and jumped 51439.31% in 2022, its largest moves.
• Sutro Biopharma's Non-Current Deffered Revenue stood at $145000.0 in 2021, then surged by 61889.66% to $89.9 million in 2022, then sank by 40.61% to $53.4 million in 2023, then sank by 76.52% to $12.5 million in 2024, then slumped by 83.82% to $2.0 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $2.0 million (Q4 2025), $3.8 million (Q3 2025), and $6.9 million (Q2 2025), per Business Quant data.